Double-blind randomized treatment of poststroke depression using nefiracetam

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 20, Issue 2, 2008, Pages 178-184

  Robinson, Robert G ^a   Jorge, Ricardo E ^a   Clarence Smith, Kathleen ^b  

^a UNIVERSITY OF IOWA   (United States)

^b CSK Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEFIRACETAM; PLACEBO; 2 PYRROLIDONE DERIVATIVE; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STROKE; TREATMENT RESPONSE; COMPARATIVE STUDY; DOSE RESPONSE; MENTAL HEALTH; MIDDLE AGED; NEUROLOGIC EXAMINATION; RETROSPECTIVE STUDY; TIME;

AGED; AGED, 80 AND OVER; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PSYCHOTROPIC DRUGS; PYRROLIDINONES; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS;

EID: 85047685693     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2008.20.2.178     Document Type: Article

References (40)

1. Astrom M, Adolfsson R, Asplund K: Major depression in stroke patients: a 3-year longitudinal study. Stroke 1993; 24:976-982
2. Pohjasvaara T, Leppavuori A, Siira I, et al: Frequency and clinical determinants of poststroke depression. Stroke 1998; 29:2311-2317
3. Morris PLP, Robinson RG, Raphael B: Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatr Med 1990; 20:349-364
4. Lincoln NB, Flannaghan T: Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial. Stroke 2003; 34:111-115
5. Lipsey JR, Robinson RG, Pearlson GD, et al: Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984; 1:297-300
6. Wiart L, Petit H, Joseph PA, et al: Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31:1829-1832
7. Andersen G, Vestergaard K, Lauritzen L: Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25:1099-1104
8. Choi-Kwon S, Han SW, Kwon SU, et al: Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006; 37:156-161
9. Robinson RG: The Clinical Neuropsychiatry of Stroke, 2nd ed. New York, Cambridge University Press, 2006
10. Currier MB, Murray GB, Welch CC: Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992; 4:140-144
11. Murray GB, Shea V, Conn DK: Electroconvulsive therapy for poststroke depression. J Clin Psychiatry 1986; 47:258-260
12. Jorge RE, Robinson RG, Tateno A, et al: Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 2004; 55:398-405
13. Kimura M, Kanetani K, Imai R, et al: Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 2002; 17:121-125
14. Hougaku H, Matsumoto M, Hata R, et al: [Therapeutic effect of lisuride maleate on post-stroke depression]. Nippon Ronen Igakkai Zasshi 1994; 31:52-59 (Japanese)
15. Tsuchiya Y, Takahashi Y, Jindo T, et al: Comprehensive evaluation of canine renal papillary necrosis induced by nefiracetam, a neurotransmission enhancer. Eur J Pharmacol 2003; 475:119-128
16. Nishizaki T, Matsuoka T, Nomura T, et al: Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol Pharmacol 1998; 53:1-5
17. Kitano Y, Komiyama C, Makino M, et al: Effects of nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats. Epilepsia 2005; 46:1561-1568
18. Moriguchi S, Marszalec W, Zhao X, et al: Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther 2003; 307:160-167
19. Narahashi T, Moriguchi S, Zhao X, et al: Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull 2004; 27:1701-1706
20. Zhao X, Yeh JZ, Narahashi T: Post-stroke dementia: nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann NY Acad Sci 2001; 939:179-186
21. Ando T, Takagi N, Takagi K, et al: Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats. Eur J Pharmacol 2005; 507:49-56
22. Jin J, Watabe S, Yamamoto T: Nefiracetam improves the impairment of local cerebral blood flow and glucose utilization after chronic focal cerebral ischemia in rats. Pharmacology 2002; 64:119-125
23. Otomo E, Kogure K, Hirai S, et al: [Clinical utility of DM-9384 (Nefiracetam) in patients with aftereffect following cerebrovascular disorders: a comparative double-blind study with idebenone]. Rinsho Iyaku (J Clin Ther Med) 1994; 10:1871-1918 (Japanese)
24. Wing JK, Cooper JE, Sartorius N: The Measurement and Classification of Psychiatric Symptoms: An Instructional Manual for the PSE and CATEGO Programs. New York, Cambridge University Press, 1974
25. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
26. Robinson RG, Starr LB, Kubos KL, et al: A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke 1983; 14:736-744
27. Beck AT, Steer RA: Beck Depression Inventory Manual. San Antonio, Tex., The Psychological Corporation, 1987
28. Hayee MA, Akhtar N, Haque A, et al: Depression after stroke-analysis of 297 stroke patients. Bangladesh Med Res Counc Bull 2001; 27:96-102
29. Berg A, Psych L, Palomaki H, et al: Poststroke depression: an 18-month follow-up. Stroke 2003; 34:138-143
30. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48:314-318
31. Grace J, Nadler JD, White DA, et al: Folstein vs modified minimental state examination in geriatric stroke: stability, validity, and screening utility. Arch Neurol 1995; 52:477-484
32. Forer S, Granger CV: Functional Independence Measure. Buffalo, The Buffalo General Hospital State University of New York at Buffalo, 1987
33. Brott T, Adams HP, Olinger CP, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-870
34. Narushima K, Chan KL, Kosier JT, et al: Does cognitive recovery after treatment of poststroke depression last? A 2-year followup of cognitive function associated with poststroke depression. Am J Psychiatry 2003; 160:1157-1162
35. Chemerinski E, Robinson RG, Kosier JT: Improved recovery in activities of daily living associated with remission of post-stroke depression. Stroke 2001; 32:113-117
36. Khan A, Brodhead AE, Kolts RI, et al: Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39:145-150
37. Lam RW, Andersen HF: The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006; 39:180-184
38. Fruehwald S, Gatterbauer E, Rehak P, et al: Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003; 250:347-351
39. Robinson RG, Schultz SK, Castillo C, et al: Nortriptyline versus fluoxetine in the treatment of depression and in short term recovery after stroke: a placebo controlled, double-blind study. Am J Psychiatry 2000; 157:351-359
40. Khan A, Schwartz K, Kolts RL, et al: Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 2007; 62:65-71